期刊
ARCHIVES OF PHARMACAL RESEARCH
卷 37, 期 1, 页码 24-30出版社
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-013-0272-6
关键词
Central nervous system; Blood-brain barrier; Nanotechnology; Nano-enabled delivery; Receptor-mediated transcytosis
资金
- (Global RNAi Carrier Initiative) of KIST
The development of drugs to treat disorders of the central nervous system (CNS) faces difficulties in achieving penetration of a drug through the blood-brain barrier (BBB) and allowing the drug to reach its intended target in the brain. There have been strategies to improve drug delivery to the brain through endogenous transport pathways such as passive diffusion, endocytosis, and active transport. Among various strategies, nano-enabled delivery systems offer a promising solution to improve the uptake and targeted delivery of drugs into the brain. Various nanocarriers including liposomes, bolaamphiphiles and nanoparticles can be used as a means to encapsulate drugs, either alone or in combination with targeting ligands. Moreover, most of materials used in nanocarrier fabrication are both biodegradable and biocompatible, thereby increasing the clinical utility of them. Here, we review the possibility to employ nano-enabled materials for delivery of drug across the BBB and the recent advances in nanotechnologies for therapy of the CNS diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据